Wakamoto: Sales Up 2.1% Resulting in Smaller Losses

Wakamoto Pharmaceutical posted sales of ¥4,737 million, up 2.1% compared to the corresponding period of the previous year, driven by good sales of a latanoprost ophthalmic solution and the ophthalmic surgery adjuvant MaQaid Intravitreal Injection (triamcinolone). Losses decreased with operating...read more